Search for: "PAR PHARMACEUTICALS"
Results 201 - 220
of 303
Sorted by Relevance
|
Sort by Date
6 Sep 2006, 12:18 pm
Falabella was fined approximately with U$8,000,000 and Almacenes París was fined U$5,000,000. [read post]
27 Feb 2009, 5:00 am
USA, Inc (Orange Book Blog) (FDA Law Blog) (Patent Baristas) (Law360) (Patent Docs) (Patent Prospector) (Patently-O) (GenericsWeb) (Hal Wegner) Famvir (Famciclovir) – US: Teva loses bid to toss Novartis wilful infringement claims over Famvir (Law360) Fentora (Fentanyl) – US: Barr alleges Cima and Cephalon’s patent suit just a delay tactic (Law360) Integrilin (Eptifibatide) – US: Schering alleges patent infringement following Teva’s Para IV… [read post]
8 Nov 2016, 11:53 pm
Among the generic drug companies experiencing this share price decline were Allergan, Teva Pharmaceuticals, and Endo Pharmaceuticals. [read post]
1 Apr 2009, 2:07 am
In the settlement, UBS agreed to buy the securities back from retail investors at par value, or to make up the difference to retail investors who had already sold for less than par. [read post]
26 Feb 2024, 1:36 am
As the EBA pointed out in par. 95 of Decision G 0002/21, it is a rather abstract test. [read post]
Music broadcasting at the dentist’s and in hotel rooms. CJEU clarifies “communication to the public”
25 Mar 2012, 2:10 am
The CJEU concluded the analysis holding that the exemption to the payment of the equitable remuneration contained in art. 10, par. 1, lett. [read post]
13 Dec 2018, 4:05 pm
MSD was granted an SPC for the product ezetimibe, if desired in the form of a pharmaceutically acceptable salt thereof, on the basis of its patent EP 0 720 599 (the Basic Patent). [read post]
29 Apr 2008, 7:49 pm
Nevertheless, the '589 patent uses "consisting of" language in its description of the pharmaceutical formulations. [read post]
30 Sep 2022, 12:40 pm
Consequently, such companies will be treated on par with other Indian companies, and will be subject to less regulation. [read post]
8 May 2009, 8:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs) General Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch) Flu crisis could lead to compulsory licences (Managing… [read post]
26 Oct 2011, 2:30 am
Par files suit to stop government from expanding its reach (FDA Law Blog) US: Preparing for Mayo v. [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes jury… [read post]
7 Sep 2011, 4:22 am
Apotex (Patently-O) Glivec (Imatinib mesylate) – India: The Glivec patent saga – its raining recusals (Spicy IP) Glivec (Imatinib mesylate) – India: Supreme Court to hear Novartis challenge to India’s patent law (IP Watch) Lo Loestrin Fe (Norethindrone acetate / Ethinyl estradiol / Ferrous fumarate) – US: Warner Chilcott files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs) Lumigan (Bimatoprost) – US: Allergan files… [read post]
19 Jul 2018, 10:15 am
Some research points to two causes of the high cost in the United States: 1) high pharmaceutical cost; and 2) high wages for health care workers.Notably, two pharmaceutical companies, Novartis and Pfizer, recently announced that they would not implement pharmaceutical price increases on certain drugs. [read post]
19 Aug 2009, 5:41 am
(Patent Docs) US: BIO files amicus brief in Bilski (Patent Docs) US: Jim Greenwood on data exclusivity and healthcare innovation (BiotechBlog) (IP Watchdog) (Patent Docs) US: European biosimilars market may hint at limited US threat (GenericsWeb) US: Chris Hansen on the Myriad lawsuit (Patents4Life) Products Effexor (Venlafaxine) – US: Wyeth files suit alleging Alphapharm’s Enlafax infringes its Venlafaxine patent; Generic Health, which recently registered… [read post]
26 Sep 2023, 3:11 am
Accordingly, the BRPTO is trying to hit a target of deciding cases within 24 months from filing “on par with the best international practices and will benefit its users”. [read post]
3 Mar 2015, 7:56 am
” Ideally, nursing homes would not substitute dangerous pharmaceutical drugs for increased human interaction and care. [read post]
9 Apr 2007, 7:30 am
From the FDA News item entitled "FDA Announces Voluntary Withdrawal of Pergolide Products":The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva. [read post]
29 Oct 2008, 12:14 pm
" At least thee companies (Par Pharmaceutical Companies, MBIA and Blockbuster) have committed to providing an advisory vote in 2009; A number of companies where shareholders have approved say on pay have not implemented the practice. [read post]
21 Mar 2018, 1:34 pm
Une de ces unicités a récemment refait surface dans la décision du Federal Circuit dans Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc.: la mise en vente pouvant faire anticiper un dépôt de brevet américain. [read post]
